- Home
- CRBP vs FORA Comparison
CRBP vs FORA Comparison
Compare CRBP & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- FORA
- Stock Information
- Founded
- CRBP 2009
- FORA 2014
- Country
- CRBP United States
- FORA United States
- Employees
- CRBP N/A
- FORA N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- FORA Computer Software: Prepackaged Software
- Sector
- CRBP Health Care
- FORA Technology
- Exchange
- CRBP Nasdaq
- FORA Nasdaq
- Market Cap
- CRBP 73.4M
- FORA 62.7M
- IPO Year
- CRBP N/A
- FORA N/A
- Fundamental
- Price
- CRBP $6.03
- FORA $1.96
- Analyst Decision
- CRBP Strong Buy
- FORA Strong Buy
- Analyst Count
- CRBP 10
- FORA 1
- Target Price
- CRBP $60.89
- FORA $5.00
- AVG Volume (30 Days)
- CRBP 207.2K
- FORA 30.3K
- Earning Date
- CRBP 05-06-2025
- FORA 05-13-2025
- Dividend Yield
- CRBP N/A
- FORA N/A
- EPS Growth
- CRBP N/A
- FORA N/A
- EPS
- CRBP N/A
- FORA N/A
- Revenue
- CRBP N/A
- FORA $20,153,263.00
- Revenue This Year
- CRBP N/A
- FORA $13.31
- Revenue Next Year
- CRBP $150.00
- FORA N/A
- P/E Ratio
- CRBP N/A
- FORA N/A
- Revenue Growth
- CRBP N/A
- FORA N/A
- 52 Week Low
- CRBP $4.64
- FORA $1.85
- 52 Week High
- CRBP $61.90
- FORA $4.03
- Technical
- Relative Strength Index (RSI)
- CRBP 49.07
- FORA 46.06
- Support Level
- CRBP $5.68
- FORA $1.90
- Resistance Level
- CRBP $6.29
- FORA $2.08
- Average True Range (ATR)
- CRBP 0.46
- FORA 0.12
- MACD
- CRBP 0.19
- FORA 0.02
- Stochastic Oscillator
- CRBP 84.24
- FORA 41.02
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.